Adjuvanted inactivated rabies virus-vectored Lassa virus vaccine in healthy adults: a phase 1 trial - Scorecard - MDSpire

Adjuvanted inactivated rabies virus-vectored Lassa virus vaccine in healthy adults: a phase 1 trial

  • By

  • Justin R. Ortiz

  • Drishya Kurup

  • Adam C. Kaufman

  • Sabrine Ben Hamed

  • Allison M. LaRocco

  • Kirsten E. Lyke

  • Sarah M. Litts

  • Shrimati Datta

  • Yuanyuan Liang

  • Megan F. McGilvray

  • Jeannie A. Losignor

  • Jennifer J. Oshinsky

  • Kari V. Palmer

  • Ifayet PL Johnson-Mayo

  • Gabrielle Scher

  • Uthra Balakumar

  • Anisha Chandwani

  • Rekha R. Rapaka

  • Meagan E. Deming

  • Joel V. Chua

  • Christoph Wirblich

  • Wilbur H. Chen

  • Kathleen M. Neuzil

  • Marcela F. Pasetti

  • Matthias J. Schnell

  • June 9, 2026

  • 0 min

Share

Clinical Scorecard: Phase 1 Trial of an Adjuvanted Inactivated Rabies Virus-Vectored Vaccine for Lassa Virus in Healthy Adults

At a Glance

CategoryDetail
Condition
Key MechanismsZoonotic viral disease caused by Lassa virus (LASV), transmission details need citation.
Target Population
Care Setting

Key Highlights

  • Add citation for 'LASSARAB vaccine demonstrated protective efficacy in preclinical studies.'

Guideline-Based Recommendations

Diagnosis

    Management

    • Add source for 'Supportive care is the primary management strategy for Lassa fever.'

    Monitoring & Follow-up

      Risks

        Patient & Prescribing Data

        Healthy adults aged 18–50 years.

        LASSARAB vaccine formulated with aPHAD-SE adjuvant is under investigation for safety and immunogenicity.

        Clinical Best Practices

        • Ensure each practice is cited from the source.

        Related Resources & Content

        Original Source(s)

        Adjuvanted inactivated rabies virus-vectored Lassa virus vaccine in healthy adults: a phase 1 trial

        • by Justin R. Ortiz, Drishya Kurup, Adam C. Kaufman, Sabrine Ben Hamed, Allison M. LaRocco, Kirsten E. Lyke, Sarah M. Litts, Shrimati Datta, Yuanyuan Liang, Megan F. McGilvray, Jeannie A. Losignor, Jennifer J. Oshinsky, Kari V. Palmer, Ifayet PL Johnson-Mayo, Gabrielle Scher, Uthra Balakumar, Anisha Chandwani, Rekha R. Rapaka, Meagan E. Deming, Joel V. Chua, Christoph Wirblich, Wilbur H. Chen, Kathleen M. Neuzil, Marcela F. Pasetti, Matthias J. Schnell

        • June 9, 2026

        Related Content

        AKT-mediated phosphorylation of ZDHHC5 promotes NOD1 palmitoylation and innate immune signaling

        Anti-NMDAR and anti-MOG antibody double-positive encephalitis temporally associated with cytomegalovirus detection in cerebrospinal fluid: a case report

        Risk of disseminated tuberculosis and other infections after neonatal Bacillus Calmette–Guérin vaccination in infants with in-utero exposure to tumor necrosis factor-α inhibitors